Synthetic Biology: Amplifying Throughput in Discovery at Marginal Cost
This article was originally published in Start Up
Executive Summary
An example of the looming power of synthetic biology, one of its first start-ups, Codon Devices, is providing researchers with hundreds of specified protein variants using automated, microarray-based fabrication methods. Its platform could help address pharma's productivity problem by decreasing the size of a discovery pipeline and shrinking the development timeline, and position the company to negotiate downstream payments for its efforts based on the success of clients' development programs.
You may also be interested in...
The Climate for Investing in Platform Technologies
The founder and CEO of Flagship Ventures, Noubar Afeyan, points to several reasons why early-stage investing should be on the upswing.
The Climate for Investing in Platform Technologies
The founder and CEO of Flagship Ventures, Noubar Afeyan, points to several reasons why early-stage investing should be on the upswing.
A Creative Approach to Third World Markets and to one Start-Up's First Financing
A new three-way agreement between the University of California, Berkeley (UCB), the Gates Foundation, Amyris Biotechnologies Inc., and the Institute for OneWorld Health (IOWH) showcases one approach to creating affordable drugs for third-world markets that aren't attractive to for-profit companies-with incentives for all participants.